Head-To-Head Survey: SAGE Therapeutics (SAGE) versus Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals (NASDAQ: ORMP) and SAGE Therapeutics (NASDAQ:SAGE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Oramed Pharmaceuticals and SAGE Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oramed Pharmaceuticals $2.46 million 45.10 -$10.48 million ($0.77) -10.03
SAGE Therapeutics N/A N/A -$158.98 million ($6.87) -22.15

Oramed Pharmaceuticals has higher revenue and earnings than SAGE Therapeutics. SAGE Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Oramed Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, SAGE Therapeutics has a beta of 2.97, suggesting that its share price is 197% more volatile than the S&P 500.

Institutional and Insider Ownership

1.9% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 95.0% of SAGE Therapeutics shares are held by institutional investors. 27.5% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of SAGE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oramed Pharmaceuticals and SAGE Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals 0 0 2 0 3.00
SAGE Therapeutics 1 1 12 0 2.79

Oramed Pharmaceuticals currently has a consensus target price of $22.50, indicating a potential upside of 191.45%. SAGE Therapeutics has a consensus target price of $171.21, indicating a potential upside of 12.53%. Given Oramed Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Oramed Pharmaceuticals is more favorable than SAGE Therapeutics.

Profitability

This table compares Oramed Pharmaceuticals and SAGE Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals -169.17% -49.94% -25.64%
SAGE Therapeutics N/A -89.46% -78.94%

Summary

Oramed Pharmaceuticals beats SAGE Therapeutics on 9 of the 13 factors compared between the two stocks.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply